159 related articles for article (PubMed ID: 35875418)
1. Bone-Related Extramedullary Disease in Newly Diagnosed Myeloma Patients is an Independent Poor Prognostic Predictor.
Wang Y; Liu A; Xu T; Yin J; Chen W
Clin Med Insights Oncol; 2022; 16():11795549221109500. PubMed ID: 35875418
[TBL] [Abstract][Full Text] [Related]
2. [Effects of extramedullary disease on patients with newly diagnosed multiple myeloma].
Tao Y; Jin SW; Wang Y; Tang SJ; Liu YF; Xu J; Pan MM; Zhang WP; Mi JQ
Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):48-54. PubMed ID: 36987723
[No Abstract] [Full Text] [Related]
3. [The therapeutic effect and prognostic value of oligoclonal bands after autologous stem cell transplant in patients with multiple myeloma].
Shi QL; Xu Y; Wang J; Jin YY; Zhang R; Li JY; Chen LJ
Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):514-520. PubMed ID: 38317363
[No Abstract] [Full Text] [Related]
4. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
[TBL] [Abstract][Full Text] [Related]
5. Survival trends and prognostic factors of patients with newly diagnosed multiple myeloma accompanied with extramedullary disease.
Wang J; Shen N; Shen X; Zhang R; Jin Y; Li J; Chen L
Ann Med; 2023; 55(2):2281657. PubMed ID: 38086395
[No Abstract] [Full Text] [Related]
6. Clinical characteristics and survival outcomes of newly diagnosed multiple myeloma patients presenting with extramedullary disease: A retrospective study.
Gao S; Li Q; Dong F; Yang P; Chen Y; Wang J; Wang Y; Jing H
Leuk Res; 2022 Apr; 115():106793. PubMed ID: 35248783
[TBL] [Abstract][Full Text] [Related]
7. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
[TBL] [Abstract][Full Text] [Related]
8. 1q21+ is associated with poor prognosis in newly diagnosed multiple myeloma patients with extramedullary disease: a retrospective study.
Gao S; Dong F; Yang P; Chen Y; Wang Y; Wang J; Shi Y; Jing H
Ann Hematol; 2024 Jun; 103(6):1979-1987. PubMed ID: 38206369
[TBL] [Abstract][Full Text] [Related]
9. Favorable Long-Term Outcomes with Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma Patients with a Positive Result On
Cho HJ; Baek DW; Kim JH; Lee J; Chung YK; Jung SH; Song GY; Ahn SY; Ahn JS; Yang DH; Lee JJ; Kim HJ; Hong CM; Jeong SY; Min JJ; Sohn SK; Moon JH
Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):113-120. PubMed ID: 34598908
[TBL] [Abstract][Full Text] [Related]
10. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
[TBL] [Abstract][Full Text] [Related]
11. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
[TBL] [Abstract][Full Text] [Related]
12. [Autologous stem cell transplantation improves outcomes of patients with multiple myeloma receiving proteasome inhibitors and lenalidomide treatment].
Ning X; Wei X; Guo X; Wei Q; Huang F; Fan Z; Xu N; Sun J; Feng R; Liu Q; Wei Y
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Aug; 41(9):1420-1425. PubMed ID: 34658359
[TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of 264 multiple myeloma patients.
Geng C; Liu N; Yang G; Liu A; Leng Y; Wang H; Li L; Wu Y; Li Y; Chen W
Oncol Lett; 2013 Feb; 5(2):707-713. PubMed ID: 23420708
[TBL] [Abstract][Full Text] [Related]
14. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
15. [Clinical Analysis of 46 Cases of Multiple Myeloma with Extramedullary Disease].
Chao Y; Fan L; Gao XY; Ma YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):115-121. PubMed ID: 33554807
[TBL] [Abstract][Full Text] [Related]
16. Advances in the treatment of extramedullary disease in multiple myeloma.
Li Y; Sun Z; Qu X
Transl Oncol; 2022 Aug; 22():101465. PubMed ID: 35679743
[TBL] [Abstract][Full Text] [Related]
17. Liquid extramedullary disease in multiple myeloma strongly predicts a poor prognosis and is associated with bortezomib resistance gene upregulation.
Ji J; Guo R; Ma J; Cui Y; Li Y; Sun Z; Li J; Fan L; Qu X
Clin Chim Acta; 2023 Aug; 548():117497. PubMed ID: 37479009
[TBL] [Abstract][Full Text] [Related]
18. Clinical Characteristics and Prognostic Analysis of Multiple Myeloma with Extramedullary Disease: A SEER-Based Study.
Li G; Song YP; Lv Y; Li ZZ; Zheng YH
J Oncol; 2021; 2021():6681521. PubMed ID: 33603785
[TBL] [Abstract][Full Text] [Related]
19. Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.
Zannetti BA; Tacchetti P; Pantani L; Gamberi B; Tosi P; Rocchi S; Cellini C; Ronconi S; Pezzi A; Mancuso K; Rizzello I; Caratozzolo I; Martello M; Dozza L; Cavo M; Zamagni E
Ann Hematol; 2017 Dec; 96(12):2071-2078. PubMed ID: 29063955
[TBL] [Abstract][Full Text] [Related]
20. Identification of patients at high risk of secondary extramedullary multiple myeloma development.
Stork M; Sevcikova S; Minarik J; Krhovska P; Radocha J; Pospisilova L; Brozova L; Jarkovsky J; Spicka I; Straub J; Pavlicek P; Jungova A; Jelinek T; Sandecka V; Maisnar V; Hajek R; Pour L
Br J Haematol; 2022 Feb; 196(4):954-962. PubMed ID: 34726261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
